How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts

2020 ◽  
Vol 39 (3) ◽  
pp. 445-452 ◽  
Author(s):  
Rena Conti ◽  
Stacie B. Dusetzina ◽  
Rachel Sachs
2021 ◽  
Author(s):  
Rena Conti ◽  
Brigham Frandsen ◽  
Michael Powell ◽  
James Rebitzer

2021 ◽  
pp. 14-37
Author(s):  
Neumann Peter J. ◽  
Cohen Joshua T. ◽  
Ollendorf Daniel A

This chapter describes how prescription drug markets deviate from “normal” competitive markets. On the demand side, there is considerable uncertainty in disease prognosis and treatment effects; buyers have much less information than sellers; consumers usually do not pay directly for their prescriptions but rather have health insurance, which protects them from a drug’s full price; and physicians and insurers play a major role in consumer choices. On the supply side, firms are heavily regulated, subject to laws requiring that drugs undergo extensive testing before entering the marketplace. Monopolies are a system feature, designed to incentivize companies to invest in expensive and risky drug discovery by providing the prospect of a big payoff if the investment succeeds. Patents and market exclusivity restrict competition and provide drug developers considerable pricing power. The challenge for policymakers is how to achieve reasonable or fair drug prices in light of these market distortions.


2003 ◽  
Vol 6 (1) ◽  
Author(s):  
Meredith B. Rosenthal ◽  
Ernst R. Berndt ◽  
Julie M. Donohue ◽  
Arnold M. Epstein ◽  
Richard G. Frank

The release of clarified Food and Drug Administration (FDA) guidelines and independent changes in consumer behavior provide an opportunity to study the effects of direct-to-consumer advertising (DTCA) in the prescription drug market alongside the effects of various physician-oriented promotions. We examine the effects of DTCA and detailing for brands in five therapeutic classes of drugs, using monthly aggregate U.S. data from August 1996 through December 1999. In terms of impact of DTCA on demand, we provide evidence on two issues: (1) do increases in DTCA increase the market size of an entire therapeutic class? and (2) does DTCA increase within-class market share of advertised drugs? Our findings suggest that, for these classes of drugs, DTCA has been effective primarily through increasing the size of the entire class. Overall, we estimate that 13 to 22 percent of the recent growth in prescription drug spending is attributable to the effects of DTCA.


2019 ◽  
Vol 12 (4) ◽  
pp. 1-76
Author(s):  
Andrew T. Ching ◽  
Manuel Hermosilla ◽  
Qiang Liu

Sign in / Sign up

Export Citation Format

Share Document